ArticleJournal of the Royal Statistical Society. Series C, Applied statistics2019
Two-stage design for phase I-II cancer clinical trials using continuous dose combinations of cytotoxic agents.
Article in Journal of the Royal Statistical Society. Series C, Applied statistics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A Novel Method for Inserting Dose Levels Mid-Trial in Early-Phase Oncology Combination Studies.Statistics in medicine · 2026Article
- A narrative review of adaptive Phase I/II clinical trial designs for drug combinations in oncology.Frontiers in oncology · 2026Review
- Resistance Management for Cancer: Lessons from Farmers.Cancer research · 2024Review
- A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages.Biometrical journal. Biometrische Zeitschrift · 2023Article
- Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?Brazilian journal of biometrics · 2022Article
- Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials.Journal of the Royal Statistical Society. Series C, Applied statistics · 2022Article
- A nonparametric Bayesian method for dose finding in drug combinations cancer trials.Statistics in medicine · 2022Article
- A dose-finding design for dual-agent trials with patient-specific doses for one agent with application to an opiate detoxification trial.Pharmaceutical statistics · 2022Article
- A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations.Biometrical journal. Biometrische Zeitschrift · 2020Article
- A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades.Stats · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
We present a two-stage phase I/II design of a combination of two drugs in cancer clinical trials. The goal is to estimate safe dose combination regions with a desired level of efficacy. In stage I, conditional escalation with overdose control is used to allocate dose combinations to successive cohorts of patients and the maximum tolerated dose curve is estimated as a function of Bayes estimates of the model parameters. In stage II, we propose a Bayesian adaptive design for conducting the phase II trial to determine dose combination regions along the MTD curve with a desired level of efficacy. The methodology is evaluated by extensive simulations and application to a real trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.